iRhythm to Acquire VitalConnect for $287.5M to Build Broad Cardiac Intelligence Platform
iRhythm Holdings agreed to acquire VitalConnect for about $287.5M. The deal includes $237.5M cash from iRhythm’s balance sheet and $50M in iRhythm common stock, plus up to $30M interim working capital financing before closing. iRhythm expects closing by end-2026 and projects revenue growth accretion in 2027 while keeping a 15% adjusted EBITDA margin.
How this was made
The 30-second read
Why it matters
The disclosed purchase price, funding mix, and 2027 financial targets provide a concrete framework for modeling IRTC’s post-close growth and margin trajectory, while also highlighting deal execution and regulatory approval as key near-term uncertainties.
Market read
This is a material strategic M&A announcement with explicit consideration terms and stated 2027 accretion and EBITDA margin targets, making it actionable for IRTC deal-risk and valuation modeling.
What to watch
Regulatory approval timing and the interim working capital financing structure could drive deal-risk repricing before closing.
Background
iRhythm’s Zio patch is positioned as long-term continuous ECG monitoring, while VitalConnect adds FDA-cleared mobile cardiac telemetry and multi-parameter biosensing.
Ticker impact
iRhythm agreed to acquire VitalConnect for about $287.5M, paying $237.5M cash plus $50M stock, targeting 2027 accretion.
Likely positive near-term sentiment on deal announcement, with follow-through dependent on regulatory/closing progress and integration assumptions.
The article discloses specific consideration mix, funding source, interim financing, and explicit 2027 accretion and 15% adjusted EBITDA margin targets.
Market effects
Signals consolidation in cardiac monitoring and expansion from ambulatory patch monitoring toward multi-vital and inpatient telemetry platforms.
Primarily US healthcare services and medtech M&A sentiment.
Limited direct global read-through, but supports broader trend toward integrated remote patient monitoring and biosensor platforms.
Counterpoint
Accretion and 15% adjusted EBITDA margin targets may be optimistic if integration costs, reimbursement dynamics, or device adoption lag.
Key entities
- public_companyiRhythm Holdings, Inc.
Acquirer entering a definitive agreement to buy VitalConnect for about $287.5M.
- private_companyVitalConnect, Inc.
FDA-cleared wearable biosensor platform provider being acquired to expand iRhythm’s cardiac monitoring capabilities.
